{"id":69697,"date":"2025-10-22T16:43:29","date_gmt":"2025-10-22T11:13:29","guid":{"rendered":"https:\/\/vajiramandravi.com\/current-affairs\/?p=69697"},"modified":"2025-10-25T17:45:14","modified_gmt":"2025-10-25T12:15:14","slug":"mam01-monoclonal-antibody","status":"publish","type":"post","link":"https:\/\/vajiramandravi.com\/current-affairs\/mam01-monoclonal-antibody\/","title":{"rendered":"MAM01 Monoclonal Antibody"},"content":{"rendered":"<h2><b>MAM01 Monoclonal Antibody Latest News<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">A novel monoclonal antibody named MAM01, developed by US researchers has demonstrated strong protection against malaria in an early clinical trial.<\/span><\/p>\n<h2><b>About MAM01 Monoclonal Antibody<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">MAM01 is a <\/span><b>monoclonal antibody<\/b><span style=\"font-weight: 400;\"> developed to prevent <\/span><b>malaria infection.<\/b><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">It&#8217;s designed to target a highly conserved region of the <\/span><b>Plasmodium falciparum circumsporozoite protein<\/b><span style=\"font-weight: 400;\">, blocking infection <\/span><b>before the parasite reaches the bloodstream.<\/b><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The trial found that MAM01 provided <\/span><b>dose-dependent full protection<\/b><span style=\"font-weight: 400;\"> against the malaria parasite with minimal side effects.<\/span><\/li>\n<\/ul>\n<h2><b>Key Features of MAM01 Monoclonal Antibody<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Administration:<\/b> <b>Single injection<\/b><span style=\"font-weight: 400;\"> of a long-acting antibody and provide immediate, months-long protection.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">It is particularly beneficial for <\/span><b>young children<\/b><span style=\"font-weight: 400;\"> and <\/span><b>pregnant women<\/b><span style=\"font-weight: 400;\"> in malaria-endemic regions.<\/span><\/li>\n<\/ul>\n<h3><b>What are Monoclonal antibodies?<\/b><\/h3>\n<ul>\n<li><span style=\"font-weight: 400;\">Monoclonal antibodies (mAbs) are <\/span><b>laboratory-made proteins<\/b><span style=\"font-weight: 400;\"> that <\/span><b>mimic the body\u2019s natural immune defenses.<\/b><\/li>\n<li><span style=\"font-weight: 400;\">The word \u201cmonoclonal\u201d refers to the fact that the antibodies created in <\/span><b>the laboratory are clones.<\/b><span style=\"font-weight: 400;\"> They are exact copies of one antibody.<\/span><\/li>\n<li aria-level=\"1\"><b>Production:<\/b>\n<ul>\n<li><span style=\"font-weight: 400;\">They are produced by <\/span><b>cloning a single type of immune cell, known as a B cell<\/b><span style=\"font-weight: 400;\">, to generate large quantities of identical antibodies.<\/span><\/li>\n<li><span style=\"font-weight: 400;\">This process creates highly specific antibodies that target a particular antigen, which could be a virus, bacteria, cancer cell, or other disease-related molecule.<\/span><\/li>\n<li><b>Specificity:<\/b><span style=\"font-weight: 400;\"> They can be designed to recognize and bind to a particular target molecule with great precision. This specificity reduces the risk of unintended side effects.<\/span><\/li>\n<\/ul>\n<\/li>\n<li><b>Application:<\/b><span style=\"font-weight: 400;\"> They are used in a variety of medical applications, including the treatment of cancer, autoimmune diseases, and infectious diseases.<\/span><\/li>\n<\/ul>\n<p><b>Source:<\/b> <strong><a href=\"https:\/\/ddnews.gov.in\/en\/new-monoclonal-antibody-shows-early-promise-against-malaria\/\" target=\"_blank\" rel=\"nofollow noopener\">DD News<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MAM01 Monoclonal Antibody developed to prevent malaria infection.<\/p>\n","protected":false},"author":24,"featured_media":70167,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[3348],"class_list":{"0":"post-69697","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-upsc-prelims-current-affairs","8":"tag-mam01-monoclonal-antibody","9":"no-featured-image-padding"},"acf":[],"_links":{"self":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/69697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/comments?post=69697"}],"version-history":[{"count":0,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/69697\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media\/70167"}],"wp:attachment":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media?parent=69697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/categories?post=69697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/tags?post=69697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}